## PhenoPath Toll-free: 1.888.92.PHENO P 1.206.374.9000 F 1.206.374.9009 Duest Diagnostics Company F 1.206.374.9009

 	$\mathbf{n}$	/	$\mathbf{n}$		
 н		/	S	ы.	
 		/ 8	<b>_</b>	п.	
 	-		-		

A Quest Diagnostics Company		F 1.206.374.9009 www.phenopath.com			PHENOPATH USE ONLY						
			REQUESTING ENTITY NAME & ADDRESS								
Facility specimen collected at					Block(s), submitted stained slides and report will be returned to the Ordering Physician at						
Collection Date Collection Time					the address/FAX listed below (unless otherwise requested): Name (Client ID)						
					Add1						
Multiple specimens submitted	Multiple specimens submitted: 🗌 Test Separately 🗌 Select Best 🔹 Combine										
Pathology Report:	Pathology Report:  Included  Not Available					Zip					
Specimen ID Sublabel Specimen Source						<u> </u>			FAX#:		
						Ordering Physician Name NPI#					
					Ordering provider signature, credentials & date requested (required by certain payers)						
		ATION /ASC		wirement)		<i>(</i> 1 1 1 -	NA 11			·· · · · · · · · · · · · · · · · · · ·	
				uirement)						sity requirements. You should is and treatment of the patient.	
Fixative: 🗌 10% NBF (Neutral Fixation duration (please circle				known	BILLIN	IG INFO (If c	omplete and	accurate pa	tient billing infor	mation is not provided,	
Collection Time: AN						ath may bill th ] Insurance			g entity		
PATIENT INFORMATION					BILL:       Insurance       Patient       Requesting entity         PO#       PO not required       ICD-10						
Name (Last, First, MI)					*If 3 <sup>rd</sup> -pa	ty billing is requ	lested, a copy	of face sheet a	nd front/back of pat	tient's ins/Medicare card must be th from billing a 3rd-party entity	
			🗆 Male		† It reques	sting entity has l	been selected,	, ENTIRE billing	demographics MUS henoPath will bill th	51 be documented below	
	DOB			🗌 Female	Attn:		Entity Nam				
Medical Record #	Medical Record #				Department Address						
					City, ST Zip						
Medical Record #         Medical Record #         Address         Address         Phone         CONTACT INFORMATION         Person completing form         Date         G/TC         G/TC         MALK protein (p80)         N/A ALK (for lung CA)         Alpha-1 antitrypsin*         Alpha-1 antitrypsin*         Alpha-1 antitrypsin*         Alpha-1 antitrypsin*         Alpha-fetoprotein (AFP)         Amyloid A         Amyloid P         Arginase-1         ATRX         BAP1         bcl-2 (clone 124)         bcl-2 (clone SP66)         bcl-10         BCMA         BCMA <t< td=""><td colspan="4">Address</td><td colspan="5">Billing Contact Phone #: FAX#:</td><td></td></t<>	Address				Billing Contact Phone #: FAX#:						
? ☆ Phone					TREATING PHYSICIAN (for billing purposes, write/type in the name of the treating physician)						
					Mail/fax copy of report to treating physician; IF ALL INFO BELOW IS NOT COMPLETED, report will NOT be faxed or mailed						
inpatient	Inpatient 🗌 Outpatient 🗌 Non-Hospital Patient					Physician Name:					
	CONTACT INFORMATION				Facility Name:						
Person completing form	Person completing form				Mailing Address						
Date		Phone			Phone #	:			FAX#:		
G/TC	G/TC		G/TC		G/	тс		G/TC		G/TC	
Z Adenovirus	CD14		EBV	by ISH (EBEF	R-1)	IMP3		🗋 🗋 Nesti			
🛱 🔲 🔲 ALK protein (p80) 🛛 🔅	CD15			R		Inhibin-alp INI-1 (SMA)		(2F11	)	Smooth muscle actin (1A4)	
Image: Second state state       Image: Second	CD20			SP1)	R	INPP4B			2		
명 [ ] AMACR (p504s) [ 평 ] AMACR (p504s) [ 평 ] Amyloid A	CD22				Ā	Kappa by I				SSt2A	
e Amyloid Beta*	🗋 🗋 CD25		🔲 🗋 FOXI	P1	ğ	□ Keratin 5/	6		/4	🗋 🗋 Synaptophysin	
Amyloid P	CD30		Gale	ctin-3		Keratin 7		<b>— —</b> p16 <b>—</b> p40			
Arginase-1	CD33		Gast	rin A-3		<ul> <li>Keratin 19</li> <li>Keratin 20</li> </ul>	I	D D p53		🔲 🛄 TCR-ßF1 🔲 🔲 TCR-delta	
© □ □ BAP1 © □ □ bcl-2 (clone 124)	🗋 🗋 CD35			FP-15		🔲 Keratins (A	AE1/AE3)	🗖 🗖 p63	TRK	🔲 🔲 TdT 🛄 🛄 Thrombomodulin	
C → D → bcl-2 (clone SP66)	CD38		GFAI	agon amine Synth		<ul> <li>Keratins (0</li> <li>Keratins (34</li> <li>Ki-67 (MIB</li> </ul>		Panci	reatic polypeptide	<ul> <li>Thyroglobulin</li> <li>TIA-1</li> </ul>	
	🗋 🗋 CD45		🗖 🗖 Glyc	ophorin A		🗋 Ki-67 (SP6	5)	D PAX5	Virus	🔲 🔲 Toxoplasma gondii	
D BCMA	BCMA DCD56 (NCAM) DGlypican-3					<ul> <li>Lambda by</li> <li>Lambda by</li> <li>Langerin</li> </ul>	/ IHC y ISH*	PAX8     PD-1     N/A PD-L	(CD279)	<ul> <li>Transthyretin</li> <li>Treponema Pallidum</li> </ul>	
출 □ □ Beta-catenin 옷 □ □ Bg8 (blood group 8)	🔲 🛄 CD61 🔲 🛄 CD68 (M	(P-1)		27me3 1E-1		LEF1		N/A PD-L	1 (28-8)	(spirochetes) <b>(spirochetes)</b>	
Bob-1	CD71	,	🗖 🗖 нса	(Beta-HCG)*	• 🗖	🔲 LMO2		🔲 🛄 PD-L	1 (E1L3N)	🗋 🗋 TŤĚ-1	
BRG1 (SMARCA4)	CD/9a CD103		🔲 🗋 Hep	cobacter pylo B core antige	en*	<ul> <li>Lysozyme</li> <li>Mammagle</li> <li>MART-1 (N</li> </ul>	obin	N/A PD-L	1 (SP263)	<ul> <li>Uroplakin</li> <li>Varicella Zoster Virus</li> <li>Villin</li> </ul>	
° Ц Ц с-MYC .≝ □ □ Calcitonin	CD138		🗍 🗍 Hepl	B surface ant Par1 (Hepato	cyte) 🗋	MART-1 (M Merkel cel			2	🗋 🗋 Vimentin	
2 Calcitonin 2 Caldesmon 2 Caldesmon 2 Calponin	CD163			2 by IHC (no re 2 by IHC		polyomavi Mesothelii			planin (D2-40) mavirus (SV40)	□ □ vWF □ □ WT-1	
e □ □ Calretinin □ □ □ CAM 5.2	CDH17	(o-kit)	(run	FISH if 2+)	Ā	MLH1 MNDA		🔲 🛄 PR (1	E2)	🗋 🛄 ZAP-70	
Calcitonin     Caldesmon     Calponin     Caltorinin     Caltorinin     Caltorinin     Caltorinin     Caltorinin     Cartonic Anhydrase IX     Cathonic Anhydrase IX     Cathonic K	CDX2			8		☐ MOC-31		antig		G = staining with interp TC = staining w/o interp	
Calponin Calponin Calretinin CAM 5.2 Carbonic Anhydrase IX Cathepsin K	🔲 🔲 CEA (mo	ogranin A		345		MSH2 MSH6		PTEÑ     PU.1			
$\begin{array}{c} \hline \\ \hline $	🗋 🔲 Clusteri 🗋 🔲 CMV	in		1/11	Ē	MUC4		N/A ROS-     S-100	1 )		
	🗋 🛄 CXCL13					Myelopero	xidase		4		
	Cyclin E			0.1.0		MyoD1 Myogenin			2 3		
P     CD4       CD5     CD7       CD7     CD8       CD10 (CALLA)     Image: Call of the string of the strin	DOG1 🗋 🗖 DOG1	erin	IgG4	α IgG		Myoglobin Napsin A	^		04		
<ul> <li>Reflex and additional testing</li> <li>№</li> </ul>	OTES: Most tests list	ted in a panel may be				write-in request if no 366.927.4366 for mo		* Send-out test	ing not performed by F send-out and agree to	PhenoPath; by ordering the test, you accept financial responsibility.	
i Denormed al an additional charge i n	r other disease state									and a second sec	
Send: Reqs (List req						ts 🗌 RPMI [			Date Nee		

## By submitting a specimen with this requisition form, you agree:

- 1) The information provided on this form and accompanying paperwork is complete and accurate.
- 2) If the information is not accurate, and PhenoPath cannot obtain reimbursement for services that have been requested and provided, Client agrees to accept financial responsibility.
- 3) If the test order is ambiguous, PhenoPath may contact client to determine intent. Testing may be delayed.
- Requests for testing PhenoPath does NOT perform (for current test menu, consult PhenoPath's website www.phenopath.com or contact Client Services at 1.206.374.9000. or Toll-free at 1.888.92.PHENO (1.888.927.4366);
  - a) PhenoPath may forward specimens to an alternate facility for testing it does not perform, upon authorization by Client.
  - b) PhenoPath will manage return of applicable specimen to Client.
  - c) By signing the authorization form, Client agrees to pay for authorized services that are not paid for by a third party. PhenoPath can only bill for professional services provided by PhenoPath.

**ICD-10** – All providers, laboratories, institutions, hospitals, and other providers ordering laboratory testing to be performed by PhenoPath Laboratories must provide all clinically relevant ICD-10-CM diagnosis codes for all testing submitted.

**Direct Bill Law** – Washington is a "direct-bill" state for anatomic pathology services (http://apps.leg.wa.gov/rcw/default.aspx?cite=48.43.081, RCW 48.43.081). This means that for specimens originating in the State of Washington, PhenoPath can only send a bill to the entity that ordered the services (or to the patient or their insurance).

**MEDICARE COVERAGE DETERMINATIONS** – PhenoPath is a Medicare participating provider, and is subject to the local coverage determinations (LCD) of the Medicare Administrative Contractor (MAC) for Jurisdiction F, Noridian Healthcare Solutions, Contractor No. 02402. Additional information can be obtained online at: https://www.noridianmedicare.com/partb/coverage/active.html.

**MEDICARE MEDICAL NECESSITY REQUIREMENTS** – When ordering laboratory tests that are billed to Medicare/Medicaid or other federally funded programs, the following requirements may apply:

- 1) Only tests that are medically necessary for the diagnosis or treatment of the patient should be ordered. Medicare does not pay for screening tests, except for certain specifically approved procedures, and may not pay for non-FDA-approved tests or tests considered experimental.
- 2) If there is reason to believe that Medicare will not pay for a test, the patient should be informed, and asked to sign an Advanced Beneficiary Notice (ABN) to indicate whether he/she accepts responsibility for the cost of the test if Medicare denies payment.
- 3) The ordering physician must provide all clinically relevant ICD-10 diagnosis codes, not a narrative description, in order to support the medical necessity of each test ordered. Providing ICD-10 codes on the Requisition will avoid unnecessary phone calls to physician and client offices as well as delays in service to patients to obtain medical necessity documentation. PhenoPath may contact Client to obtain diagnosis information for reasons including, but not limited to the following:
  - A diagnosis code is not provided.
  - The provided diagnosis appears inconsistent with the patient's demographic, the patient's medical condition or the testing services being ordered.
  - The provided diagnosis does not meet the coverage criteria as supporting medical necessity for testing services covered by a Medicare LCD.
- 4) Organ- or disease-oriented panels should be billed to Medicare only when every component of the panel is medically necessary. The OIG takes the position that a physician who orders medically unnecessary tests for which Medicare reimbursement is claimed may be subject to civil penalties. PhenoPath- and client-customized panels should be billed to Medicare only when every component of the customized panel is medically necessary. PhenoPath offers groups of tests based on accepted clinical practice.

Advanced Beneficiary Notice ("ABN") – An ABN, Form CMS-R-131, is a standardized notice you must issue to a Medicare beneficiary before providing certain Medicare Part B (outpatient) or Part A (limited to hospice, home health agencies [HHAs], and Religious Nonmedical Healthcare Institutions only) items or services. You must issue the ABN when:

- You believe Medicare may not pay for an item or service;
- Medicare usually covers the item or service; and
- Medicare may not consider the item or service medically reasonable and necessary for this patient in this particular instance. You should only provide ABNs to beneficiaries enrolled in original (fee-for-service) Medicare. ABNs allow beneficiaries to make informed decisions about whether to get services and accept financial responsibility for those services if Medicare does not pay. The ABN serves as proof the beneficiary knew prior to getting the service that Medicare might not pay. If you do not issue a valid ABN to the beneficiary when Medicare requires it, you cannot bill the beneficiary for the service, and you may be financially liable if Medicare doesn't pay. You may also use the ABN as an optional (voluntary) notice to alert beneficiaries of their financial liability prior to providing care that Medicare never covers. ABN issuance is not required to bill a beneficiary for an item or service that is not a Medicare benefit and never covered.
- If you order a test that does not meet Medicare's medical necessity guidelines, it is important that you complete an ABN and have it signed by the patient at the time of service. This will allow you and PhenoPath to bill the patient for the services provided if Medicare does not reimburse us for the test(s) and if the patient has accepted the financial responsibility. Medicare defines medical necessity as services that are: reasonable and necessary, for the diagnosis or treatment of an illness or injury or to improve the functioning of a malformed body member, and not excluded under another provision of the Medicare Program. All services reported to the Medicare Program by healthcare professionals must demonstrate medical necessity through the use of International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) diagnostic coding carried to the highest level of specificity for the date of service.

Physician Clinical Consultant: PhenoPath's pathologists are available to discuss appropriate testing and test ordering with ordering physicians.